After Mick Jagger’s heart surgery, it might be time to buy certain medical stocks

By all accounts, Mick Jagger’s heart surgery–a procedure known as a transcatheter aortic valve replacement (TAVR)–was a complete success. It shouldn’t be long before he’s out of the hospital and recuperating at home. If all goes well, he’ll be ready to tour with The Stones in a couple of months.

An EKG conducted during a pre-tour physical (band members need to undergo these things for insurance purposes) uncovered a sticky valve, something that’s not uncommon in a 75-year-old man. In the past, a fix required open-heart surgery, but not anymore.

A side effect from Mick’s surgery is a boost in interest in companies that make the gear for TAVR procedures. People of certain vintages have been following Mick’s progress and may elect to speak to their doctors about having the same operation. At the very least, they may make an appointment to determine if they also have sticky valces.

Keep an eye on Edwards Lifesciences Corp, Medtronic PLC, and Boston Scientific.

(Via The Toronto Star)

Alan Cross

is an internationally known broadcaster, interviewer, writer, consultant, blogger and speaker. In his 40+ years in the music business, Alan has interviewed the biggest names in rock, from David Bowie and U2 to Pearl Jam and the Foo Fighters. He’s also known as a musicologist and documentarian through programs like The Ongoing History of New Music.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.